Page 16 - PHESGO (PERTUZUMAB-TRASTUZUMAB) - Product Monograph

 New injections should be given at least 1 inch from the previous site on healthy
skin and never into areas where the skin is red, bruised, tender, or hard.
 During the treatment course with fixed-dose SC combination of trastuzumab

and pertuzumab, other SC medications should preferably be injected at
different sites.

Patients currently receiving IV PERJETA + trastuzumab can be transitioned
®
to fixed-dose SC combination of trastuzumab and pertuzumab if eligible.

7.2. Additional dosing considerations and dose modifications

Dose sequencing 39
 In patients receiving an anthracycline-based regimen for eBC, administer

fixed-dose SC combination of trastuzumab and pertuzumab following
completion of the anthracycline.
 In patients receiving fixed-dose SC combination of trastuzumab and

pertuzumab for eBC with docetaxel or paclitaxel, administer docetaxel or
paclitaxel after fixed-dose SC combination of trastuzumab and pertuzumab.
 In patients receiving fixed-dose SC combination of trastuzumab and

pertuzumab for mBC with docetaxel, administer docetaxel after fixed-dose
SC combination of trastuzumab and pertuzumab.

Transitioning from IV PERJETA (pertuzumab) + trastuzumab to
®
fixed-dose SC combination of trastuzumab and pertuzumab 39

In patients receiving Fixed-dose SC combination of trastuzumab
IV PERJETA + trastuzumab and pertuzumab as a maintenance dose
®
with <6 weeks since their of 600 mg, 600 mg, 20,000 units/10 mL and
last dose every 3 weeks for subsequent administrations
Administer

In patients receiving Fixed-dose SC combination of trastuzumab
IV PERJETA + trastuzumab and pertuzumab as an initial dose of
®
with ≥6 weeks since their 1,200 mg, 600 mg, 30,000 units/15 mL,
last dose followed by a maintenance dose of 600 mg,

Administer 600 mg, 20,000 units/10 mL every 3 weeks
for subsequent administrations

M-AE-00000086 16